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Abstract
With the ongoing COVID-19 pandemic, the use of alcohol-based antiseptics by the general public
has greatly increased. While this form of antimicrobial is effective in stopping the spread of both
bacterial and viral infections, little research has been conducted in the development of alcohol
tolerance by microorganisms or its mechanisms. In this study, experimental evolution was
conducted on four separate strains of Staphylococcus aureus to determine if tolerance can develop
towards moderate to high concentrations of ethanol. Once ethanol tolerance was established in the
evolved populations, whole genome sequencing was performed to identify the potential mutations
responsible for the observed alcohol tolerance.
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Chapter 1: Background
Clinical Relevance of Staphylococcus aureus
Staphylococcus aureus is a Gram-positive, facultative anaerobic bacterium and an opportunistic
pathogen [1]. As a known human pathogen, S. aureus can cause a wide variety of diseases
depending on the location of infection [2]. Common diseases caused by an S. aureus infection
include cellulitis (skin and soft tissue) [3], pneumonia (lung tissue) [4], bacteremia and
sepsis (bloodstream) [5], osteomyelitis and arthritis (bone and joint tissue) [6], and
endocarditis (epithelial tissue of the heart) [7]. In rare cases, S. aureus infections can also cause
necrotizing fasciitis and pyomyositis [8]. Sepsis caused by S. aureus is especially dangerous
because it can lead to the spread of inflammation and infection throughout the body, which may
result in shock, organ failure, and death [9]. Toxins are also produced and secreted by S. aureus,
including enterotoxins A and B, that cause various food-borne illnesses if ingested [10].
Enterotoxin B specifically plays a crucial role in causing toxic shock syndrome as well. This
superantigen interacts with the MCH class II molecules of antigen-presenting cells, resulting in an
overactive response of the host’s immune system [11]. This immune response can lead to fever,
hypertension, and tachycardia, which can result in organ failure and death if untreated [12]. The
variety of disease caused by a single pathogen demonstrates the unique clinical significance of
S. aureus.
Despite its ability to cause a variety of diseases, Staphylococcus aureus also is a natural
part of the human microbiota, with approximately 25% of the population’s skin, respiratory tract,
and gut colonized by S. aureus [13][14]. S. aureus is able to thrive on and within the human body
due to its high salt tolerance, its ability to survive in both the presence and absence of oxygen, as
well as grow in a broad range of temperatures (15°C to 45°C) [15][16]. In addition, S. aureus
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commonly form biofilms, which assist in the attachment and protection of the bacterial cells within
the matrix [17]. These biofilms aid in the bacteria’s ability to cause disease by allowing for human
tissue colonization following cell attachment and biofilm maturation, as well as protection from
the host’s immune response [17]. Another S. aureus mechanism for evading the host’s immune
system is with the expression of protein A [18]. Protein A, which is encoded by the spa gene, is a
bacterial surface protein that is capable of binding to the Fc regions of antibodies as well as the
Fab regions of B-cell receptors [18]. Binding of these regions results in the suppression of the
immune response.
Staphylococcal infections are obtained in one of two environments: healthcare-acquired or
community-acquired [19]. As the names implies, healthcare-acquired (HA) S. aureus is
obtained within healthcare systems, including doctor offices and hospitals, whereas communityacquired (CA) S. aureus is obtained within the general population. The main modes of
transmission within these environments are direct contact, such as skin-to-skin contact, and
indirect transmission via fomites [20][21]. Fomites in particular greatly aid in the transmission of
S. aureus within healthcare systems, with one study finding that the bacteria can survive for up to
3 weeks on cotton, 8 weeks on polyester, and over 3 months on polyethylene [21]. Due to these
separate environments, HA S. aureus and CA S. aureus strains also exhibit a unique set of
genotypes and phenotypes [19]. For example, one of the defining traits of CA strains are the
presence of genes that code for Panton-Valentine leucocidin (PVL) toxins [22]. PVL toxins are
two-component toxins that are secreted and assemble to cause neutrophil lysis [23]. This cell lysis
aids in the development of symptoms associated with Staphylococcus aureus infections. In
contrast, HA strains typically display higher levels of drug resistance compared to that of
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CA strains due to increased exposure to antibiotics in these settings [19]. This resistance to
antibiotics observed in S. aureus poses a growing concern within healthcare systems.

Staphylococcus aureus Antibiotic Resistance Profiles
With its discovery in 1928 by Alexander Fleming, penicillin became the first medical antibiotic,
mass produced and distributed to treat bacterial infections in hospital patients [24]. After being
awarded the 1945 Nobel Prize in Medicine and Physiology, Fleming gave an interview with The
New York Times and forewarned that the misuse of penicillin, such as its prescription for illnesses
not caused by a bacterial infection or not fully completing the prescribed dosage, would lead to
resistance developing in bacteria [25][24]. Due to these antibiotic misusages, a resistance to
penicillin did in fact arise in many bacteria, with approximately 60% of healthcare-associated
S. aureus strains being resistant to penicillin by 1950, and over 80% by 1960 [26][27].
Community-acquired S. aureus soon followed suit, with 80% showing resistance to penicillin by
the early 1970s [27]. Today, we see this same trend emerge with a wide variety of bacteria to the
numerous antibiotics used to treat infections.
Like other bacteria, S. aureus begins to show signs of antibiotic resistance after exposure.
Antibiotics act as a selective pressure towards the bacterium, allowing evolution to favor the
organisms with genetic mutations that are able to counter the effects of the antibiotic [28]. Due to
frequent (and often unnecessary) exposure to antibiotics in clinical environments, some strains of
S. aureus have developed resistances to multiple antibiotics. These strains of bacteria, termed
“superbugs,” result in higher morbidity rates due to multiple drug resistances, and can in some
cases have enhanced virulence and transmission [28]. Because these strains have been exposed to
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several types of antibiotics, multiple resistance mechanisms have arisen to allow for bacterial
survival [28].
Antibiotic resistant strains of S. aureus, particularly methicillin-resistant Staphylococcus
aureus (MRSA), can cause life-threatening infections since these strains have become resistant to
the typical treatment methods [19]. There are also strains of S. aureus that are susceptible to
methicillin and related antibiotics, classified as methicillin-sensitive strains (MSSA) [29].
Methicillin, a semisynthetic narrow spectrum penicillin derivative, is a β-lactam antibiotic, a class
of antibiotics that contains a β-lactam rings that disrupts bacterial cell wall synthesis by preventing
the crosslinking of peptidoglycan [30]. β-lactam rings have a high affinity towards transpeptidase,
also referred to as penicillin-binding protein PBP2a, which is the enzyme responsible for the
peptidoglycan crosslinking within the bacterial cell wall [31]. β-lactam antibiotics, including
oxacillin and methicillin, are then able to bind to PBP2a and inhibits its function. One mechanism
of resistance towards β-lactam antibiotics is conferred by the mecA gene, which encodes a variant
of the PBP2a protein that has a reduced affinity for β-lactam rings [31]. This gene is associated
with the mobile gene element Staphylococcal cassette chromosome mec (SCCmec), which is
known to produce protein A, an immune system evasion molecule, and is used to classify various
methicillin-resistant S. aureus strains [32]. SCCmec types I, II, and III are associated with
HA-MRSA strains, whereas types IV and V are often associated with CA-MRSA strains [33].
Another mechanism for bacteria to combat β-lactam antibiotics is the production of β-lactamase,
an enzyme that is able to deactivate β-lactam rings through cleavage by the hydrolysis its amide
bond [34]. Two types of β-lactamase enzymes have been identified in MRSA that vary in
hydrolysis efficiency due to point mutations that have accumulated over time [35].
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One option for treating MRSA infections is using vancomycin, which is considered the last
resort antibiotic for treatment [36]. Vancomycin is able to treat Gram-positive bacteria with
β-lactam resistances because it is a glycopeptide antibiotic as oppose to a β-lactam antibiotic [37].
Glycopeptide antibiotics, like β-lactam antibiotics, disrupt the formation of the bacterial cell wall.
However, glycopeptide antibiotics inhibit both the transpeptidation and transglycosylation during
peptidoglycan assembly [38]. This class of antibiotic targets and inactivates lipid II, which is the
precursor molecule embedded in the plasma membrane responsible for peptidoglycan
synthesis [39]. Because of this distinct mechanism of action, glycopeptide antibiotics, such as
vancomycin, are highly effective against bacteria with β-lactam resistances, such as MRSA.
Unsurprisingly, resistance has also been observed for glycopeptide antibiotics. One form of
vancomycin resistance observed in S. aureus is the production of VanA, a protein that modifies
the carboxyl terminus of lipid II, reducing the affinity of the antibiotic [38]. Another observed
form of resistance is a result of the mutations in the genes coding for the RNA polymerase
β subunit [40]. Even though the mechanism of resistance remains unknown, a variety of mutations
with these genes have been associated with increased vancomycin resistance numerous times [40].
Vancomycin-resistant S. aureus (VRSA) have started to emerge in healthcare settings, with the
first reported isolate discovered in 2002 [36]. Once developed, these different antibiotic resistance
mechanisms can then be spread between S. aureus strains through horizontal gene transfer
mechanisms including conjugation [41].
Daptomycin, a lipopeptide antibiotic, is often used as an alternate treatment for methicillinresistant Staphylococcus aureus, as well as a treatment option for infections that are unable to be
alleviated by vancomycin [42]. Daptomycin, which is ineffective on its own, interacts with calcium
molecules to form bactericidal complexes [43]. These complexes then interact with the
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phosphatidylglycerol within the bacterial cell membrane, resulting in membrane depolarization
and ultimately cell death [42][43]. Various mechanisms of daptomycin resistance in S. aureus have
been discovered within laboratory settings. Similar to what was observed with vancomycin
resistance, mutations to the RNA polymerase β and β’ subunits have been associated with the
development of daptomycin resistance [43]. Another gene mutation that results in this phenotype
is mutations to the WalKR gene, a two-component regulatory system that is essential in bacterial
cell wall synthesis [44]. Mutations of this gene are associated with the generation of a thick cell
wall, which is believed to result in the increase of resistance to antibiotics [44]. Research continues
to investigate the mechanisms of these genetic mutations on antibiotic resistance development.

Alcohol as an Antiseptic
One of the most effective methods to prevent transmission of pathogenic bacteria is the application
of biocides or antiseptics. Alcohol-based antiseptics are commonly used in both healthcare
facilities and within the general public as a method of disinfecting hands and sanitizing surfaces.
With the ongoing COVID-19 pandemic, the use of alcohol-based hand sanitizer has increased,
with reported sales increasing over 1000% between 2019 and 2021 [45]. While this form of
disinfectant is proven to be successful in deactivating the SARS-CoV-2 virus, little research has
been performed on how repetitive alcohol exposure affects the skin microbiota, including
Staphylococcus aureus.
The two most common alcohols used in alcohol-based antiseptics are ethanol or
isopropanol, and are most effective with concentrations between 60% and 95% [46][47]. To be
considered effective, an alcohol-based hand sanitizer must present at least a 3.5 log10 reduction in
bacterial count (0.032% survival) after 30 seconds of exposure time [48]. For proper usage, the
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FDA and CDC recommend a volume of 1.1 mL to be applied for at least 15 seconds [49]. Both
ethanol and isopropanol are able to kill various bacterial species by disrupting the lipid membrane
of the bacterium, resulting in cell lysis [46]. The alcohol is also able to denature proteins produced
by the microorganism, as well as a potential to inhibit protein synthesis through mRNA
uncoupling [47].
With frequent alcohol exposure in healthcare systems, the development of alcohol
tolerance have been observed in other Gram-positive bacterial species, such as Enterococcus
faecium [48]. One study found that 139 E. faecium isolates collected from two Australian hospitals
over a 19-year period display an increased tolerance to isopropyl alcohol, with one isolate
exhibiting only a 0.45 log10 reduction in bacterial count following the treatment of
70% isopropanol [48]. To determine the rational of this tolerance, genome sequencing was
performed for the E. faecium isolate, Ef_aus0233. It was found that a mutation occurred in the
rpoB gene, which encodes the β subunit of RNA polymerase. Mutations in this gene have also
been connected with resistance to rifampicin in E. faecium and other Gram-positive bacteria, in
which the mutation results in a lower affinity of the RNA polymerase to the antibiotic [48][50].
Other mutations were also found in the gene sequence for a galactoside symporter, as well as in
the gene sequence for two phosphotransferase system proteins. Allelic exchanges to create targeted
mutations did not individually result in increased alcohol tolerance, but rather a combination of
multiple genetic mutations found across several loci resulted in the alcohol tolerance, suggesting
that the phenotype is polygenic [48]. While this study shows alcohol tolerance can develop in
Enterococci species, little research has been performed to determine if similar mechanisms can be
found in other Gram-positive bacteria, such as S. aureus. There is also little research investigating
the how the frequent use of alcohol-based antiseptics, such as hand sanitizers, and the development
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of alcohol tolerance effects S. aureus, either in the environment or as part of the natural human
microbiota.

Use of Experimental Evolution
One approach to investigate the mechanisms of alcohol tolerance development in Staphylococcus
aureus is through evolution experiments. With an evolutionary experiment approach, bacteria is
cultured under a selective pressure, in this case high concentrations of ethanol, which leads to rapid
adaptive mutations that can be observed in real time [51]. Benefits to this approach include short
generation time, high replication of bacterial populations, and simple growing conditions [52]. Use
of experimental evolution also allows for standardization of conditions that ensured all bacterial
populations are exposed to the same selective pressure for the same duration of time. This approach
is utilized in the ongoing evolution experiment with Escherichia coli conducted by Richard
Lenski [53]. In this particular experiment, which has been running since 1988, strains of E. coli
are observed for fitness and adaption by natural selection [53]. Even though this study does not
implement a strong selective pressure, it still demonstrates the use of experimental evolution to
investigate the dynamics of bacterial adaptation and evolution [53].
One common approach to accomplish used to conduct evolution experiments is serial
transferring, which relies on the regular consistent dilution of bacterial populations in fresh media
for evolving the strains [52]. This method allows for the removal of waste products, as well as the
addition of fresh nutrients and space needed for cell growth and division within the batch culture.
Serial transfer, the method utilized for the Lenski evolution experiment, offers many benefits as a
research tool. For instance, serial transfer is simple and cost effective to be performed in any
laboratory, with minimal maintenance and resources required throughout the duration of the
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experiment [52]. This allows for the study of multiple strains and replicates to occur
simultaneously during the experiment. Despite its ease of execution, serial transfer can be laborintensive, especially if multiple replications are being tested continuously. It is also difficult to
maintain consistent conditions throughout the experiment, including a varying population size or
genetic bottlenecking between each cycle [52]. However, there are ways to overcome these
challenges in the lab. For example, the testing of multiple replicates of each strain can help
normalize the data generated. In addition, deviations of the serial transfer method can be adapted
to further specialize the experiment [52]. One way to implement this is to introduce a changing
environment to the culture, with the selective pressure being applied outside the batch culture,
resulting in a consistent amount of stress over time and a more gradual increase in population
size [52].
This method is used to apply a strong selective pressure to a bacterial culture in the research
conducted by Gabriel Perron on the development of resistance to pexiganan in Pseudomonas
fluorescens and Escherichia coli [54]. In this study, cultures were exposed daily to the antibacterial
peptide pexiganan, with doses doubling every ten transfers, and grown in environments that did
not contain the compound [54]. Over time, this allowed for the proliferation of selected bacterial
lines that displayed resistance. Resistance levels of the ancestral strains were calculated and
compared to that of the evolved strains by using a minimum inhibitory concentration (MIC)
assay [54]. The result of this study revealed a significant increase of resistance in the evolved
strains, with all evolved strains displaying no reduction in growth after pexiganan exposure, while
no growth was observed for all ancestral strains following the exposure of the peptide [54]. Serial
transfer is thus a practical and customizable approach for long-term evolution experiments to gain

- 9 -

a better understanding of the adaptation and evolution of a trait due to prolonged exposure to a
selective pressure.

Genome Sequencing to Study Bacterial Adaptation
To identify the mutations that result in alcohol tolerance, bioinformatics approaches, such as whole
genome sequencing, are utilized. Bioinformatics uses computational approaches to analyze whole
genome DNA sequence data [55][56]. DNA sequencing is often outsourced to designated
sequencing cores. Evolution and re-sequence experiments rely on next-generation sequencing
technologies, such as Illumina sequencing, to return high quality short read sequence data [56][57].
Analysis of the returned short read data starts with alignment to a reference genome that
corresponds to the ancestral strain used to initiate the evolution experiment [58]. After alignment,
mutations are calculated based on differences between the aligned reads and reference genomes.
Finally, the identity and effect of each mutation is predicted using an annotated reference. Each of
these steps can be performed individually or through software such as breseq and Integrative
Genomics Viewer (IGV). Breseq is performed on the command line and utilizes various algorithms
to determine the likelihood of mutations from the short sequence reads with high confidence [59].
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Chapter 2: Materials and Methods
Staphylococcus aureus Strains
The four strains of Staphylococcus aureus that were utilized in this study were purchased from the
American Type Culture Collection: ATCC 10832, ATCC 29213, ATCC 43300, and
ATCC 700698. These four strains were chosen for their availability of a complete genome
sequence, as well as their evolutionary diversity and variations in antibiotic resistance profiles. All
strains are classified as BSL-2. Wood 46 (ATCC 10832) is a MSSA strain that was naturally
isolated and is a standard laboratory strain for S. aureus research [60]. Wichita (ATCC 29213),
which is also methicillin sensitive, was isolated from an infected wound and is commonly used in
pharmaceutical research and quality control [61]. A significant difference between these two
MSSA strains is that Wood 46 is spa negative and Wichita is spa positive [62][63].
F-182 (ATCC 43300) is a clinically isolated MRSA strain that is also oxacillin resistant [64].
Lastly, Mu3 (ATCC 700698) is another MSRA strain that was isolated form the sputum of a patient
with pneumonia, and is classified as a heterogeneous vancomycin-intermediate (hVISA), which
enables S. aureus to produce vancomycin resistant cells within its population [65].
All strains were resurrected from the freezer stock and cultured on tryptic soy agar (TSA) with
overnight incubation at 37°C. Single colonies were then transferred to tubes containing tryptic soy
broth (TSB). The TSB was incubated at 37°C with shaking for 48 hours to allow for sufficient
bacterial growth for all S. aureus strains. The Wood 46 strain demonstrated the slowest growth
time out of the four strains, requiring 48 hours to reach maximum cell density, whereas the other
three strains only required 24 hours. The broth cultures were then used to determine the survival
rates of each of the four Staphylococcus aureus strains by the alcohol tolerance assay.
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Alcohol Susceptibility Assay
To determine the number of bacteria present prior to the alcohol tolerance assay, dilution plates
down to 1×10-6 were made for each bacterial strain before exposure to alcohol. The number of
colony forming units (CFUs) formed were compared to the cultures exposed to alcohol to calculate
the survival curves for each strain of S. aureus.
Seven concentrations of ethanol were created to use in the alcohol tolerance assay, ranging
from 10% up to 70% ethanol in 10% increments. For each alcohol concentration, 1 mL of bacterial
culture was centrifuged for 60 seconds at max speed (15,000 rpm) and the supernatant was
removed to leave a pellet of cells. The pellet was then resuspended in 1 mL of ethanol for
15 seconds. To conclude the alcohol exposure, the ethanol was diluted by transferring 100 μL to
900 μL of 1x phosphate-buffered saline (PBS). 1:10 serial dilutions were performed down to
1×10-6 in 1x PBS, plated onto TSA, and incubated overnight at 37°C. Colony counts were then
made for each plate to determine the survival rates of the four S. aureus strains after the 15 second
exposure to the corresponding ethanol concentration. This experiment was performed for each
ancestral strain for each ethanol concentration to determine survival curves (Figure 1). To evaluate
the changes in bacterial survival, the number of CFUs were counted following the exposure of
each concentration of ethanol to determine survival rates and percentages for the four S. aureus
strains (Tables 1A and 1B).

Ethanol Tolerance Evolution Experiment
To study the evolutionary response of repeated acute ethanol exposure on Staphylococcus aureus,
an evolution experiment was conducted over the span of 20 days. Three separate populations of
each strain were established to monitor variations in evolution towards alcohol tolerance
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development. For each of the four S. aureus strains, a pure culture was inoculated into 5 mL of
TSB and incubated overnight with shaking for 48 hours at 37°C. A streak plate for each overnight
culture was created to select three individual colonies to be used for the evolving populations.
The evolution experiment to develop ethanol tolerance was conducted over the span of
20 days. Determined from the results of the alcohol susceptibility assay, 49% ethanol was utilized
for the alcohol concentration. This concentration was chosen to establish a standard ethanol
concentration for all four S. aureus strains that resulted in a log10 reduction between 2 and 4.
Ethanol was created using 200 proof ethyl alcohol and deionized water, and sterilized via vacuum
filtration. Each of the three populations for the four S. aureus strains were inoculated in 5 mL TSB
and incubated overnight with shaking at 37°C. 1 mL of each overnight culture was transferred to
a microcentrifuge tube and centrifuged for one minute at max speed (15,000 rpm) to create a cell
pellet. The supernatant was removed via aspiration. The pellets were then resuspended in 1 mL
49% ethanol for 15 seconds (to ensure only 15 seconds of ethanol exposure, pellet was resuspended
for 12 seconds, allowing for 3 seconds for transfer). 100 μL of the culture was transferred to
4.9 mL TSB and vortexed. TSB cultures were then incubated with shaking for 24 hours at 37°C.
This process was repeated daily for the 20-day evolution experiment (Figure 2). To keep a backlog
of each strain throughout the experiment, each population was stocked every third day and stored
at −80°C. Stocks were made using 600 μL culture and 400 μL 50% glycerol. If any interruptions
occurred during the evolution experiment, the experiment was resumed from the previously
stocked populations.
To compare the ethanol survival rates of the three evolved populations to that of the
ancestral population of each of the four S. aureus strains, another alcohol susceptibility assay was
performed. The day 0 ancestral populations and the day 20 evolved populations for each strain
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were resurrected in 5 mL TSB and incubated overnight with shaking for 48 hours. To determine
the cell count before ethanol exposure, dilutions were made for each overnight culture. 100 μL of
the 1×10-5 and 1×10-6 dilutions were plated on TSA plates and incubated overnight at 37°C. Next,
1 mL of each culture was transferred into microcentrifuge tubes and centrifuged for 60 seconds at
max speed (15,000 rpm). Supernatant was then removed via aspiration to leave a bacterial cell
pellet. The pellet was resuspended in 1 mL of 49% ethanol for 15 seconds before transferring
100 μL of culture into 900 μL 1x PBS. 1:10 dilutions were made in PBS down to 1×10-6. 100 μL
of each dilution of each culture was plated on TSA plates and incubated for 24 hours at 37°C. Plate
counts of the T15 plates were compared to that of the T0 plates to determine the survival rates for
each population.

Genomic DNA Extraction and Whole Genome Sequencing
DNA was extracted from each of the four Staphylococcus aureus ancestral strains and their three
evolved populations to investigate potential genetic mutations responsible for the observed alcohol
tolerance in the bacterial cells. To extract the DNA from the S. aureus populations, a modified
version of the QIAGEN DNeasy® Blood and Tissue Kit was used in addition of the pretreatment
for Gram-positive bacteria.
To set up the Gram-positive bacteria pretreatment, frozen stocks of each bacterial
population from the evolution experiment were inoculated into 5 mL of TSB and incubated over
night at 37°C with shaking. For each population, 3 mL of overnight culture was transferred into a
microcentrifuge tube and centrifuged for 60 seconds at max speed (15,000 rpm). After the
supernatant was removed, the bacterial cell pellet was resuspended in 180 μL enzymatic lysis
buffer and incubated for 45 minutes at 37°C. 25 μL proteinase K was then added to the culture
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along with 200 μL buffer AL (without ethanol), vortexed, and incubated at 56°C for 45 minutes.
200 μL 200 proof ethanol was added to the sample and mixed thoroughly.
To complete the DNeasy® Blood and Tissue Kit for DNA extraction, the culture was
transferred into a DNeasy Mini spin column and centrifuged at 8,000 rpm for 60 seconds. Once
the flow-through was discarded, 500 μL buffer AW1 was added to the spin column and again
centrifuged for 60 seconds at 8,000 rpm. The flow-through was removed once again, 500 μL
buffer AW2 was added to the spin column and centrifuged for 3 minutes at max speed
(15,000 rpm). The flow-through was discarded once again and the spin column was transferred to
a new microcentrifuge tube. The DNA was then eluded by adding 50 μL buffer AE to the spin
column and incubated for one minute at room temperature. After incubation, the tubes were
centrifuged for max speed (15,000 rpm) for 60 seconds.
Once collected, the extracted DNA was tested for purity using a NanoDrop
spectrophotometer. DNA samples were then sent to the Microbial Genome Sequencing Center
(MiGS) in Pittsburgh, PA for whole genome sequencing. One returned, sequence data was
analyzed using breseq, with sequence reads aligned to reference genomes obtained from the
American Type Culture Collection (ATCC). Called mutations were then confirmed manually
using IGV.

Evolved Bacterial Population Growth Curves
Bacterial growth was observed for the ancestral and three evolved populations of each
Staphylococcus aureus strain to observe any changes to the growth curves. Streak plates of all
populations were created and incubated overnight at 37°C. Using a 96-well plate, each well was
filled with 150 μL TSB and inoculated with a single colony. Each bacterial population had a
replicate of 6. A new 96-well plate with 180 μL TSB in each well was created with a 1:100 serial
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dilution created using 20 μL of the overnight culture. The overnight culture was transferred to the
matching wells of the new plate. Growth measurements were made via microplate
spectrophotometry with turbidity measured at 600 nm every 15 minutes for 48 hours. Stocks of
the original 96-well plate were created by adding 100 μL 50% glycerol to each well and storing at
−80°C. Measurements of turbidity over time can then be used to determine maximum growth rate,
carrying capacity, and population size of each population.
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Chapter 3: Results
Alcohol Susceptibility of Natural Staphylococcus aureus Isolates
This study is based on the hypothesis that bacteria will develop tolerance if repeatedly exposed to
ethanol. First, we identified four natural isolates of Staphylococcus aureus and quantified their
susceptibility to a range of ethanol concentrations. The S. aureus strains represent a diverse
collection that vary in resistance profiles and isolation sources (Table 1). To quantify ethanol
susceptibility, each strain was exposed to ethanol for 15 seconds. Bacterial counts were determined
by quantitative plate counts both pre- and post-exposure. Cell density for each strain prior to
alcohol exposure averaged at approximately 1×109 CFUs/mL, with the exception of the F-182
strain, which had a cell density between 1×107 and 1×107 CFUs/mL (Figure 3A, Table 2A).
Susceptibility was determined for ethanol concentrations ranging from 0% to 70% in increments
of 10%. The alcohol susceptibility assay revealed that an ethanol concentration of 40% or less had
no detectable effect on the viability of all four S. aureus strains (Figure 3A, Table 2A).
At 50% ethanol, survival of all four S. aureus strains decreased beyond 2 log10 reduction,
with both the Wood 46 and F-182 strains decreasing below 4 log10 reduction at this concentration
(Figure 3B, Table 2B). At 60% ethanol, Mu3 had the highest survival with a 4.43 log10 reduction,
followed by Wood 46 with a 5.16 log10 reduction. Meanwhile, the Wichita and F-182 strains
exhibited no detectable survival at 60% ethanol. By an ethanol concentration of 70%, no survival
was observed for any of the four S. aureus strains.
Next, we used this survival data to determine an appropriate ethanol concentration to use
in the evolution experiment. This ethanol concentration would impose a strong enough selective
pressure to select for mutants with increased tolerance to ethanol while still ensuring that enough
bacterial cells survive each alcohol exposure. We aimed for a log10 reduction between 2 and 4
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(between 1.00% and 0.01% survival) for each strain, which, based on our data (Figure 3B),
corresponded to 49% ethanol.

Development of Ethanol Tolerance through Experimental Evolution
The evolution experiment was initiated from the four strains of Staphylococcus aureus, each
establishing three independent populations for a total of 12 populations. Strains were exposed to
the ethanol at approximately the same time daily to allow 24 hours for bacterial growth. At the
conclusion of the 20-day experiment, susceptibility to 49% ethanol of the evolved S. aureus
populations was compared to those of the ancestral populations (Table 3). All four strains produced
at least one evolved population that demonstrated increased tolerance to high alcohol
concentrations (Figure 4).
The Wood 46 strain demonstrated the highest increase of ethanol tolerance in the evolved
strains with evolved population 1 having an average of 3.84 log10 increase in survival. On average,
the evolved populations of the Wood 46 strain had a log10 survival increase of 2.93. The Wichita
strain also demonstrated a high increase in alcohol tolerance. The three evolved populations had
an average log10 reduction of 0.51, a 2.30 log10 increase from that on the ancestral population. In
contrast, the F-182 strain exhibited the lowest increase in alcohol tolerance with only evolved
population 2 having a significant increase in alcohol tolerance (average 1.13 log10 survival
increase). The three evolved populations of the Mu3 also strain had a significant increase in ethanol
tolerance. The average log10 reduction of the evolved populations was 0.18, with population 3
having complete survival in the 49% ethanol for 2 out of the 3 replications.
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Whole Genome Sequencing to Identify Genetic Basis of Alcohol Tolerance
To identify the mutations that resulted in the development of tolerance to ethanol, whole genome
sequencing was performed on all the Staphylococcus aureus populations. This was accomplished
through genomic DNA extraction with the use of the QIAGEN DNeasy® Blood and Tissue Kit.
Once DNA was extracted from each population, samples were outsourced to the MiGS for
genome sequencing. Once performed, genome sequences and sequencing data was returned for
analysis (Table 4).
Our analysis showed multiple mutations within each of the evolved populations, including
many that were observed at 100% frequency in its respective population (Table 5). On average,
each evolved population contained 16.3 mutations, ranging between 8 and 24 (Figure 5). Among
these, several of the same mutations were observed throughout different evolved populations in
different strains. For instance, mutations in the walR, walK, and yycI genes, which encode for
proteins involved in cell wall synthesis, were found in populations derived from all ancestral
strains. In addition, several other genes were mutated within multiple populations; these genes are
predicted to encode the RNA polymerase β subunit, thioredoxin reductase, phospholipase C,
threonine phosphatase, and isochorismatase family protein YecD.
Both of the sequenced evolved F-182 populations contained a large deletion in their
genomes, removing 89-96 genes in total. Among those lost encode for various cellular functions
such as metabolism, transcription regulation, transporters, and restriction enzymes. Genes
encoding for virulence factors were also deleted, including the spa gene that encodes for
protein A, various methicillin-resistance genes, and genes utilized in biofilm formation. In
addition, all three evolved Mu3 populations had removal of the 25,109 bp plasmid, which encodes
for 27 genes. These genes encode for various virulence factors involved in antibiotic resistance,
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including membrane-associated proteins, efflux pumps, and transcriptional regulators. The nature
of these mutated genes and the frequency of their reoccurrence among various independently
evolved populations alludes to their contribution to alcohol tolerance development.

Quantifying Growth Rate as a Potential Tradeoff
Following the completion of the evolution experiment, growth curves were generated for each
population to determine if there was any tradeoff with bacterial growth to allow for the observed
increase in ethanol tolerance. Growth rates were measured via microplate spectrophotometry with
a replication of six per Staphylococcus aureus population. Averages of the OD600 measurements
were used to graph the growth curves (Figure 6). From this data, the intrinsic growth rates and
carrying capacities were determined for each of the ancestral and evolved populations (Figure 7).
Because each population evolved independently from one another, they were also analyzed
independently. In addition, mean values were calculated for each of the S. aureus
populations (Table 6).
Across the four Staphylococcus aureus strains, there was no significant change overall in
maximum growth rate between the ancestral populations and evolved populations. This
demonstrates that as S. aureus evolves to develop alcohol tolerance, generation time does not vary.
While no evolved Wood 46, Wichita, or Mu3 populations exhibited a significant change in growth
rate, with the exception of the Wood 46 evolved population 1, all evolved populations of the
F-182 strain demonstrated a significant increase in maximum growth rate. These evolved
populations on average had a generation time almost twice that of the ancestral
population (Figure 7A).
For carrying capacity, a significant increase was observed with S. aureus populations that
evolved ethanol tolerance. For both the Wood 46 and F-182 strains, all three evolved populations
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had a significant increase in carrying capacity when compared to the ancestral populations. In
contrast, all evolved populations of the Wichita and Mu3 strains did not have a significant change
in carrying capacity. However, there is a trend in the data that suggests an increase in carrying
capacity among these strains (Figure 7B). As a whole, evolved Staphylococcus aureus populations
observed an increase in carrying capacity and did not have a change in growth rate. This suggests
that growth rate was not a tradeoff for alcohol tolerance development.
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Chapter 4: Discussion
Development of Alcohol Tolerance in Staphylococcus aureus
In this study, we found that Staphylococcus aureus is capable of developing tolerance to
moderately high concentrations of ethanol following prolonged repetitive exposure. For both
MSSA strains, a significant increase in survival was observed in the evolved populations following
repeated exposure to ethanol (Figure 4). This substantial increase in alcohol tolerance may be
related to the isolation source of both strains. Since both strains are non-clinical isolates, they have
had little to no prior exposure to alcohol. Because of this, we would expect the ancestral strains to
be highly susceptible to alcohols. After the evolution experiment with repeated exposure to a
strong selective pressure like ethanol, random mutations that select for increased alcohol tolerance
will thrive and ultimately become fixed within the populations. This is what was observed with
each of the evolved populations.
For both the F-182 and Mu3 MRSA strains, a less substantial increase in survival was
observed (Figure 4). Similar to the MSSA strains, this can possibly be caused by the strain source.
Unlike the MSSA strains, F-182 and Mu3 are clinical isolated with resistance to methicillin. In
addition, the SCCmec typing of these strains suggest that they are both healthcare-acquired. This
also implies that these two strains have had previous exposure to various alcohol-based antiseptics.
This would explain the initial survival rate of the ancestral populations. The F-182 strain was the
only strain that did not exhibit a significant increase in alcohol tolerance between the ancestral
population and the evolved populations. It should be noted that the ancestral population formed
biofilms that created cell clumps when exposed to ethanol; this phenotype is absent in all three
evolved populations. This biofilm formation is a possible contributor to the higher survival rate
observed in the ancestral population and can be responsible for the non-significant survival rate
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increase of two evolved populations. The Mu3 strain demonstrated the highest survival rate out of
all the strains tested. Evolved population 3 in particular had no cell reduction for two out of the
three replicates and was able to survive 15 seconds exposure to 70% ethanol.
An increase in carrying capacity was also observed across all the evolved populations as a
whole (Figure 7). While some evolved populations did not exhibit a statistically significant
increase in carry capacity, a clear trend is observed among each S. aureus strain. It is possible that
the mutations responsible for ethanol tolerance also increase the maximum population size for
each strain. In contrast, intrinsic growth rate did not change across all evolved S. aureus
populations, illustrating growth rate was not influenced by alcohol tolerance development.
However, an increase in generation time was observed for the evolved populations of the F-182
strain, which suggests that the alcohol tolerance development contributed to the increased growth
rate observed.

Mechanisms of Alcohol Tolerance Development
Several mutations were detected in each evolved population, with some observed at 100%
frequency throughout the population (Figure 5). Many of these mutations affect the same gene
across several evolved populations. Since these populations evolved independently from one
another, there is strong evidence that these mutations are responsible for the observed alcohol
tolerance. Among these were mutations that encode for various hydrolases including
isochorismatase, threonine phosphatase, and phospholase C. These enzymes are responsible for
bacterial metabolism and maintaining homeostasis within the bacteria’s environment. Mutations
in these genes suggest an alteration in metabolism that allow for an increased tolerance to alcohol.
Similarly, genes encoding for the RNA polymerase β subunit were also mutated across
multiple evolved populations. Despite not fully understanding how these mutation in the
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RNA polymerase subunit effect the cell, there is evidence that these mutations influence bacterial
resistance to various antibiotics, and thus may also contribute to the observed tolerance [40].
Additionally, mutations with genes for thioredoxin reductase were also found across multiple
populations of the evolved S. aureus strains. As an enzyme that aids in the response to disulfide
and oxidative stressors, thioredoxin reductase is responsible for survival to reactive oxygen
species [66]. Because the metabolism of alcohol by bacteria produces reactive oxygen species as
a byproduct, mutations of the thioredoxin reductase genes may increase bacterial survival in the
presence of these toxic molecules [67].
For all evolved populations of the four Staphylococcus aureus strains, mutations were
observed in several genes that contribute to cell wall synthesis. As genes encoding for the
regulation of the two-component system WalR/WalK, alterations to these proteins would affect
the formation of the bacterial cell wall [68]. These genetic mutations suggest that alcohol tolerance
was achieved through abnormal cell wall thickening. This thickening would ultimately protect
each individual cell from ethanol exposure. It is possible that this cell wall thickening can also
protect the bacterium from other extracellular compounds that are detrimental to the cell.

Future Research
Next steps in research will further investigate the mutations responsible for the observed alcohol
tolerance. Because many of these detected mutations are involved with cell wall synthesis, further
experiments can be performed to better understand the gene products being made as well as their
function. For example, gene knockout can be constructed to determine the effect these mutations
have on the phenotypes observed.
In addition, the alcohol susceptibility of the evolved populations to ethanol will also be
explored. This will be accomplished by performing the alcohol susceptibility assay on each of the
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evolved populations as well as the ancestral strains. Similar to the protocol used, ethanol
concentrations ranging from 0% to 100% in 10% increments will be used to calculate the optimal
ethanol concentration that results in the greatest log10 reduction in colony count. This will also
determine if similar levels of tolerance are observed with antiseptic concentrations of ethanol for
each evolved population. The alcohol tolerance assay and evolution experiment will also be
completed using isopropyl alcohol as opposed to ethanol. A similar protocol used for the ethanol
susceptibility assay will be performed to determine the survival percentages for the various
isopropanol concentrations. Whole genome sequence will also be performed to determine what
mutations are responsible for the developed tolerance to isopropanol. These mutations can then be
compared to those found with ethanol tolerance to determine if similar mechanisms of tolerance
are observed.
Furthermore, future research will also investigate whether this development of alcohol
tolerance also impacts the antibiotic resistance profiles of Staphylococcus aureus. To accomplish
this, antibiotic susceptibility tests, such as the Kirby-Bauer and MIC assays, will be used to
compare the antibiotic resistance profiles of the evolved strains to that of the ancestral strains.
Since the observed mechanisms of alcohol resistance in S. aureus are similar to the mechanisms
associated with various resistances to antibiotics, it is expected that the increased alcohol tolerance
will also provide inadvertent resistance towards antibiotics commonly uses to treat
Staphylococcus aureus infections, such as β-lactam antibiotics, vancomycin, and daptomycin.
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Figure 1: Protocol schematic of the alcohol susceptibility assay. The alcohol susceptibility assay
was performed on the ancestral populations of each Staphylococcus aureus strain. 8 replicates of
the experiment were perform using separate concentrations of ethanol, ranging from 0% to 70%
in 10% increments. Ancestral strains grown to saturation. Colony counts of the T15 dilution plates
were compared to those of the T0 dilution plates to generate survival curves across the various
alcohol concentrations.
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Figure 2: Daily protocol schematic of the evolution experiment. The daily evolution experiment
protocol was performed on three replicate populations for each of the four Staphylococcus aureus
strains for a total of 20 days.
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Figure 3: Survival of Staphylococcus aureus ancestral strains decline to below -3 log10 reduction
when exposed to ethanol concentrations greater than or equal to 50%. Colony counts performed
by plate count and serial dilution. The F-182 strain demonstrated a lower carrying capacity
compared to that of the other three strains (Figure 3A). Red dashed lines indicate survival rate
range of interest chosen for the evolution experiment (Figure 3B). Survival was determined by
dividing the number of survivors after 15 seconds of ethanol exposure (T15) by the inoculum (T0).
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Figure 4: After 20 days of the evolution experiment, evolved populations of Staphylococcus aureus
have higher survival percentages to 49% ethanol than those of the ancestral populations. Means of
each population notated as black bars. Survival was calculated by dividing the number of CFUs
after 15 seconds of ethanol exposure by the inoculum. For each strain, survival for each of the
evolved populations were compared to that of the ancestral population. Statistics determined using
an unpaired t-test (n = 3, *: p < 0.05, **: p < 0.01, ***: p < 0.001). Overall, a significant increase
in ethanol tolerance between the ancestral and evolved populations was observed across all four
strains (p < 0.001).
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the 20-day evolution experiment. Mutations predicted using breseq and confirmed using IGV.
Fixed mutations were observed at 100% frequency within the population.
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Figure 6: Growth curves of ancestral and three evolved populations of Staphylococcus aureus.
Ancestral and evolved populations of Wood 46 (Figure 6A), Wichita (Figure 6B), F-182 (Figure
6C), and Mu3 (Figure 6D) were grown within individual wells of a 96-well plate with six replicates
per population. Optical density measured at 600nm using a microplate reader. Measurements were
taken every 15 minutes over a 24-hour period. Average measurements for each population were
used to generate line graph.
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Mu3

Figure 7: Growth curve metrics for the ancestral and evolved Staphylococcus aureus populations.
Intrinsic growth rate of the population (Figure 7A) and carrying capacity (Figure 7B) calculated
from microplate reader measurements taken over a 24-hour period. Error bars represent
±1 standard error (OD = 600nm). For each strain, maximum growth rate and carrying capacity for
each of the evolved populations were compared to those of the ancestral population. Statistics
determined using an unpaired t-test (n = 6, *: p < 0.05, **: p < 0.01, ***: p < 0.001). For all four
S. aureus strains, no significant difference was found in the maximum growth rate between the
three evolved populations and the ancestral populations (p = 0.114). However, a significant
increase in carrying capacity between the ancestral and evolved populations was observed across
all strains (p < 0.001).
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ATCC ID

Strain Name

Resistance Profile

Strain Source

10832

Wood 46

Methicillin Sensitive

Community Acquired

29213

Wichita

Methicillin Sensitive

Healthcare Acquired

43300

F-182

700698

Mu3

Methicillin Resistant
Oxacillin Resistant
Methicillin Resistant
Heterogeneous Vancomycin Intermediate

Healthcare Acquired
Healthcare Acquired

Table 1: Classification of Staphylococcus aureus strains. Resistance profiles of the strains studied
are categorized as methicillin sensitive (MSSA) or methicillin resistant (MRSA). Strains are also
classified by infection source, either being community-acquired (CAI) or healthcareacquired (HAI).
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Ethanol Concentration

A

Wood 46

Wichita

109

109

F-182

Mu3

0%

1.41 ×

10%

1.64 × 109

2.21 × 109

4.90 × 107

9.30 × 108

20%

1.68 × 109

1.76 × 109

1.87 × 107

7.60 × 108

30%

1.92 × 109

2.03 × 109

5.80 × 107

9.70 × 108

40%

1.36 × 109

1.46 × 109

2.90 × 107

5.00 × 108

50%

5.60 × 104

3.20 × 106

1.30 × 103

2.89 × 106

60%

9.80 × 103

0

0

3.74 × 104

70%

0

0

0

0

B
Ethanol Concentration

Cell Count (CFUs/mL)
1.95 ×

3.05 ×

107

1.00 × 109

Survival (log10 Reduction)
Wood 46

Wichita

F-182

Mu3

0%

0.00

0.00

0.00

0.00

10%

0.00

0.00

0.00

− 0.03

20%

0.00

− 0.05

− 0.21

− 0.12

30%

0.00

0.00

0.00

− 0.01

40%

− 0.01

− 0.13

− 0.02

− 0.30

50%

− 4.40

− 2.79

− 4.37

− 2.54

60%

− 5.16

NS

NS

− 4.43

70%

NS

NS

NS

NS

Table 2: Staphylococcus aureus colony counts and survival after 15 seconds exposure to several
ethanol concentrations. Bacterial plate counts were recorded for each strain tested: Wood 46,
Wichita, F-182, and Mu3 (Table 1A). For each strain, colony counts were performed on TSA
dilution plates to determine the concentration of bacterial cells per culture (CFUs/mL). Survival
rates (log10 reduction) to each concentration of ethanol were calculated for each strain (Table 1B).
0% ethanol was utilized as the control and is highlighted in blue. No bacterial survival is notated
as “NS.”
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Mu3

F-182

Wichita

Wood 46

Survival (log10 Reduction)
Replicate 1

Replicate 2

Replicate 3

Mean

Ancestral

− 4.72

− 5.26

− 4.83

− 4.94

Evolved 1

− 1.02

− 0.88

− 1.41

− 1.10

Evolved 2

− 2.43

− 2.06

− 1.87

− 2.12

Evolved 3

− 3.52

− 2.45

− 2.49

− 2.82

Ancestral

− 3.06

− 2.26

− 3.12

− 2.81

Evolved 1

− 0.35

− 0.15

− 0.55

− 0.35

Evolved 2

− 0.39

− 1.09

− 1.20

− 0.89

Evolved 3

− 0.16

− 0.21

− 0.46

− 0.28

Ancestral

− 2.00

− 1.52

− 0.93

− 1.48

Evolved 1

− 0.57

− 1.27

− 0.72

− 0.85

Evolved 2

− 0.36

− 0.15

− 0.55

− 0.35

Evolved 3

− 0.46

− 1.64

− 1.78

− 1.29

Ancestral

− 1.14

− 0.91

− 0.97

− 1.01

Evolved 1

− 0.19

− 0.21

− 0.14

− 0.18

Evolved 2

− 0.41

− 0.28

− 0.10

− 0.26

Evolved 3

− 0.01

− 0.03

− 0.25

− 0.10

Table 3: Survival for ancestral and three evolved populations of each Staphylococcus aureus strain
after 15 seconds exposure to 49% ethanol. Evolved population have higher survival (lower
log10 reduction) compared to the survival of the ancestral populations (highlighted blue).
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Wood 46
Wichita
F-182
Mu3

gDNA Concentration
(ng/μL)

Total Reads

Total bp
> Q30

Percentage bp
> Q30

Ancestral

70.5

6,740,186

942,741,498

93.778%

Evolved 1

20.2

7,402,076

1,034,224,481

93.875%

Evolved 2

31.1

6,587,654

917,278,931

93.763%

Evolved 3

23.0

6,641,460

927,647,236

93.651%

Ancestral

128.8

6,190,824

864,194,320

93.566%

Evolved 1

19.0

6,367,000

890,576,418

93.499%

Evolved 2

27.3

4,741,644

658,673,262

92.810%

Evolved 3

35.3

3,608,302

479,951,173

88.801%

Ancestral

70.4

4,195,692

581,487,338

92.574%

Evolved 1

21.4

4,278,566

593,270,041

92.630%

Evolved 2

44.6

4,586,950

632,534,875

92.144%

Evolved 3

31.7

5,454,320

755,174,757

92.482%

Ancestral

37.6

4,735,116

658,738,767

92.884%

Evolved 1

21.7

5,064,642

704,997,365

92.967%

Evolved 2

64.4

7,956,698

1,113,465,651

93.610%

Evolved 3

30.3

6,729,050

941,251,255

93.520%

Table 4: Genomic DNA extraction statistics of all Staphylococcus aureus populations. Statistics
performed by the Microbial Genome Sequencing Center (MiGS) in Pittsburgh, Pennsylvania.
Genomic DNA concentration determined using NanoDrop. Sequencing performed via Illumina
Sequencing. Q30 represents a quality score of 30 (99.9% accuracy).
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A

Wood 46 Evolved Population 1 - Predicted Mutations

Position

Mutation

Freq.

Annotation

Gene

Product

359,735

A→T

5.6%

T684T (ACA→ACT)

relA →

GTP pyrophosphokinase

695,654

A→T

7.3%

D88E (GAT→GAA)

thrB ←

Homoserine kinase

1,058,903

C→G

7.6%

intergenic (+231/+229)

OCNGBMEK_01002 → /
← pepF1_2

1,167,847

C→G

5.0%

T42S (ACT→AGT)

OCNGBMEK_01110 →

hypothetical protein

1,202,064

19 bp (x2)

8.6%

coding (246/912)

OCNGBMEK_01143 ←

Nucleotide-binding protein

1,443,710

G→A

100%

T1146I (ACA→ATA)

rpoC ←

DNA-directed RNA polymerase subunit beta'

1,447,663

G→C

8.7%

L1058V (CTT→GTT)

rpoB ←

DNA-directed RNA polymerase subunit beta

1,535,679

G→T

5.8%

D1472E (GAC→GAA)

gltA ←

Glutamate synthase [NADPH] large chain

1,828,213

G→C

9.3%

K88N (AAG→AAC)

yecD →

Isochorismatase family protein YecD

2,039,570

C→A

100%

E274* (GAA→TAA)

OCNGBMEK_01925 ←

2,041,076

T→A

5.6%

E378V (GAA→GTA)

walK ←

hypothetical protein/Oligoendopeptidase F, plasmid

hypothetical protein
Sensor protein kinase WalK

New Junction Evidence
Position

Reads (cov)

Score

Freq.

260 (0.840)

69/248

95.8%

24,507 =
= 2,816,036
24,512 =
= 2,816,040

3 (0.010)
+C

3/274

Annotation

Gene

Product

coding (186/201)

hlb_1

Phospholipase C

coding (16/825)

hlb_2

Phospholipase C

coding (181/201)

hlb_1

Phospholipase C

coding (12/825)

hlb_2

Phospholipase C

18.9%
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B

Wood 46 Evolved Population 2 - Predicted Mutations

Position

Mutation

Freq.

Annotation

Gene

Product

1,446,205

Δ9 bp

100%

coding (934-942/3624)

rpoC ←

DNA-directed RNA polymerase subunit beta'

2,038,853

G→A

100%

Q68* (CAA→TAA)

yycI ←

Two-component system WalR/
WalK regulatory protein YycI

2,256,007

G→A

6.7%

intergenic (−57/−352)

clpL ← / → ogt

ATP-dependent Clp protease ATP-binding subunit ClpL/
Methylated-DNA--protein-cysteine methyltransferase

New Junction Evidence
Position

Reads (cov)

Score

Freq.

24,507 =
10 (0.040)

9/248

= 24,520
14/248

= 1,052,639
12/250

= 2,015,342
3/272

2,791,732 =
= 2,805,657

16/236

coding (16/825)

hlb_2

Phospholipase C

coding (173/201)

hlb_1

Phospholipase C

coding (1/825)

hlb_2

Phospholipase C

coding (1260/1386)

mgtE

Magnesium transporter MgtE

coding (371/1386)

mgtE

Magnesium transporter MgtE

coding (3870/4194)

OCNGBMEK_01903

Hypothetical protein

coding (3862/4194)

OCNGBMEK_01903

Hypothetical protein

coding (1600/1617)

groL

intergenic (+457/−552)

isp/OCNGBMEK_02645

N/A

2,015,350 =

37 (0.140)

Phospholipase C

8.1%

1,053,528 =

5 (0.020)

Product

hlb_1

10.4%

2,816,051 =

20 (0.070)

Gene

5.3%

= 2,816,036

21 (0.080)

Annotation
coding (186/201)

13.3%
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60 kDa chaperonin
Intracellular serine protease/
Hypothetical protein

C

Wood 46 Evolved Population 3 - Predicted Mutations

Position

Mutation

Freq.

Annotation

Gene

Product

281,789

C→A

24.2%

H50N (CAT→AAT)

OCNGBMEK_00291 →

hypothetical protein

296,638

A→T

100%

intergenic (+727/−82)

pyk → /
→ OCNGBMEK_00301

Pyruvate kinase/IS1182 family transposase ISSau3

1,049,254

T→A

25.8%

L309* (TTA→TAA)

OCNGBMEK_00992 →

Putative transport protein

1,058,903

C→G

8.60%

intergenic (+231/+229)

OCNGBMEK_01002 → /
← pepF1_2

1,449,243

G→A

100%

S531L (TCA→TTA)

rpoB ←

1,563,705

T→G

25.1%

I13I (ATA→ATC)

OCNGBMEK_01480 ←

1,928,170

T→A

5.0%

intergenic (+275/+828)

OCNGBMEK_01816 → /
← norB_3

hypothetical protein/Quinolone resistance protein NorB

2,023,263

G→T

100%

intergenic (−102/+483)

OCNGBMEK_01908 ← /
← OCNGBMEK_01909

hypothetical protein/hypothetical protein

2,046,255

T→A

5.8%

T278S (ACT→TCT)

dnaC ←

Replicative DNA helicase

2,240,046

G→T

13.6%

A245S (GCA→TCA)

bacF →

Transaminase BacF

hypothetical protein/Oligoendopeptidase F, plasmid
DNA-directed RNA polymerase subunit beta
hypothetical protein

New Junction Evidence
Position

Reads (cov)

112,080 =

35 (0.130)
+TTCTCCGA
TTTAAAAC

3/244

74 (0.260)
+ATTAGTAAAA

5/256

1,474,861 =
112,760 =
1,533,755 =

Score

Freq.

Annotation

Gene

Product

non-coding (7/76)

OCNGBMEK_00116

tRNA-Ala

intergenic (+520/+36)

gabR/OCNGBMEK_01396

non-coding (1/76)

OCNGBMEK_00123

tRNA-Asp

non-coding (90/93)

OCNGBMEK_01456

tRNA-Ser

7.4%

HTH-type transcriptional regulatory
protein GabR/5S ribosomal RNA (partial)

20.1%
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D

Wichita Evolved Population 1 - Predicted Mutations

Position

Mutation

Freq.

Annotation

Gene

Product

1,032,042

A→T

17.3%

I464N (ATC→AAC)

murE ←

UDP-N-acetylmuramoyl-L-alanyl-D-glutamate-L-lysine ligase

1,096,077

A→T

8.8%

N327K (AAT→AAA)

pgi ←

Glucose-6-phosphate isomerase

1,239,048

G→T

7.8%

F190L (TTC→TTA)

trxB ←

Thioredoxin reductase

1,416,449

A→T

5.0%

intergenic (−47/+130)

LNEJMEBC_01363 ← /
← LNEJMEBC_01364

hypothetical protein/Phosphomevalonate kinase

1,563,072

A→T

5.8%

intergenic (−68/+575)

LNEJMEBC_01497 ← /
← treR_1

hypothetical protein/
HTH-type transcriptional regulator TreR

1,564,246

C→A

93.1%

E44* (GAG→TAG)

treR_1 ←

HTH-type transcriptional regulator TreR

1,699,839

A→T

5.3%

intergenic (+79/+52)

LNEJMEBC_01626 → /
← nanE

1,850,913

G→T

9.5%

D96Y (GAC→TAC)

yecD →

Isochorismatase family protein YecD

1,981,542

Δ12 bp

94.0%

coding (793-804/1827)

walK ←

Sensor protein kinase WalK

1,994,222

T→A

6.2%

I327F (ATT→TTT)

serS ←

Serine--tRNA ligase

2,024,904

C→A

5.0%

W465L (TGG→TTG)

yflS ←

Putative malate transporter YflS

2,208,054

G→C

24.7%

E68D (GAG→GAC)

lipR →

Putative acetyl-hydrolase LipR

2,425,363

G→T

8.6%

S167* (TCA→TAA)

lyrA ←

Lysostaphin resistance protein A

2,634,924

Δ73 bp

69.1%

intergenic (+69/−325)

fba → / → murA2

45,769

C→A

12.9%

S256I (AGC→ATC)

LNEJMEBC_02665 ←

hypothetical protein/
Putative N-acetylmannosamine-6-phosphate 2-epimerase

Fructose-bisphosphate aldolase/
UDP-N-acetylglucosamine 1-carboxyvinyltransferase 2
hypothetical protein

New Junction Evidence
Position

Reads (cov)

Score

Freq.

19 (0.070)

10/250

9.3%

= 25,918
2,744,247 =
113,850 =
1,568,003 =

48 (0.170)
+ATTAGTAAAA

10/258

Annotation

Gene

Product

coding (173/201)

hlb_1

Phospholipase C

coding (1/825)

hlb_2

Phospholipase C

non-coding (1/76)

LNEJMEBC_00126

tRNA-Asp

non-coding (90/93)

LNEJMEBC_01501

tRNA-Ser

17.0%
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E

Wichita Evolved Population 2 - Predicted Mutations

Position

Mutation

Freq.

Annotation

Gene

Product

209,347

Δ1 bp

100%

coding (347/402)

rot →

HTH-type transcriptional regulator rot

585,836

G→T

6.8%

L9926L (CTG→CTT)

LNEJMEBC_00554 →

792,634

C→T

5.9%

A288T (GCT→ACT)

sucD ←

824,113

C→G

100%

G41A (GGC→GCC)

stp ←

866,665

A→T

5.5%

S387T (TCT→ACT)

pbpB ←

1,019,447

A→T

6.2%

intergenic (−861/+482)

LNEJMEBC_00955 ← /
← LNEJMEBC_00956

hypothetical protein/hypothetical protein

1,019,470

G→C

6.2%

intergenic (−884/+459)

LNEJMEBC_00955 ← /
← LNEJMEBC_00956

hypothetical protein/hypothetical protein

1,019,479

G→A

7.0%

intergenic (−893/+450)

LNEJMEBC_00955 ← /
← LNEJMEBC_00956

hypothetical protein/hypothetical protein

1,239,041

C→A

6.6%

D193Y (GAT→TAT)

trxB ←

Thioredoxin reductase

1,239,048

G→T

8.8%

F190L (TTC→TTA)

trxB ←

Thioredoxin reductase

1,564,040

Δ9 bp

100%

coding (328-336/729)

treR_1 ←

1,850,913

G→T

6.9%

D96Y (GAC→TAC)

yecD →

1,980,433

61 bp (x2)

65.1%

duplication

LNEJMEBC_01861 ←

hypothetical protein

2,253,513

C→A

7.3%

D919E (GAC→GAA)

LNEJMEBC_02099 →

Putative surface protein

2,371,987

A→T

10.6%

S79C (AGT→TGT)

narT →

2,700,448

C→A

6.8%

intergenic (+55/+703)

LNEJMEBC_02530 → /
← ilvA

hypothetical protein
Succinate--CoA ligase [ADP-forming] subunit alpha
Serine/threonine phosphatase stp
Penicillin-binding protein 2B

HTH-type transcriptional regulator TreR
Isochorismatase family protein YecD

putative nitrate transporter NarT
5S ribosomal RNA (partial)/
L-threonine dehydratase biosynthetic IlvA

New Junction Evidence
Position
113,850 =
1,568,003 =

Reads (cov)
48 (0.230)
+ATTAGTAAAA

Score
7/258

Freq.

Annotation

Gene

Product

non-coding (1/76)

LNEJMEBC_00126

tRNA-Asp

non-coding (90/93)

LNEJMEBC_01501

tRNA-Ser

19.5%
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F
Position

Wichita Evolved Population 3 - Predicted Mutations
Mutation

Freq.

Annotation

Gene

Product

179,548

A→G

32.4%

intergenic (−97/−215)

LNEJMEBC_00208 ← /
→ LNEJMEBC_00209

489,710

T→A

8.2%

L24Q (CTA→CAA)

scpB →

589,974

G→T

11.0%

intergenic (−278/−173)

LNEJMEBC_00557 ← /
→ LNEJMEBC_00558

823,825

T→A

13.8%

D137V (GAT→GTT)

stp ←

1,032,042

A→T

13.6%

I464N (ATC→AAC)

murE ←

1,096,077

A→T

9.6%

N327K (AAT→AAA)

pgi ←

Glucose-6-phosphate isomerase

1,230,353

C→T

9.8%

E54K (GAA→AAA)

cggR ←

Central glycolytic genes regulator

1,239,048

G→T

11.6%

F190L (TTC→TTA)

trxB ←

Thioredoxin reductase

1,239,059

C→A

7.5%

D187Y (GAT→TAT)

trxB ←

Thioredoxin reductase

1,345,053

G→T

8.7%

intergenic (−54/−307)

LNEJMEBC_01292 ← /
→ sle1_1

1,541,643

G→C

18.9%

Q265E (CAA→GAA)

rsmA ←

1,567,571

G→A

44.3%

intergenic (−40/+429)

treP_1 ← / ← LNEJMEB
C_01501

1,569,918

T→A

5.7%

D1475V (GAT→GTT)

gltA ←

1,832,715

G→A

6.4%

I410I (ATC→ATT)

LNEJMEBC_01744 ←

1,986,374

A→T

5.4%

L284I (TTA→ATA)

dnaC ←

Replicative DNA helicase

2,003,434

A→T

10.4%

N216K (AAT→AAA)

recF ←

DNA replication and repair protein RecF

2,282,319

T→A

8.1%

intergenic (+32/−111)

LNEJMEBC_02129 → /
→ nikA

2,308,841

G→A

5.3%

R307Q (CGA→CAA)

panE →

2,353,545

C→A

6.0%

S102R (AGC→AGA)

LNEJMEBC_02192 →

hypothetical protein

2,595,521

C→A

6.3%

A1172E (GCA→GAA)

LNEJMEBC_02434 →

hypothetical protein

2,688,875

G→A

100%

G76D (GGC→GAC)

rsbU →

Phosphoserine phosphatase RsbU

2,690,500

G→A

100%

G135D (GGT→GAT)

rsbW →

Serine-protein kinase RsbW

2,737,982

A→T

8.9%

H336Q (CAT→CAA)

ktrB_2 ←

Ktr system potassium uptake protein B

1,494

C→T

5.1%

intergenic (+308/−240)

LNEJMEBC_02607 → /
→ LNEJMEBC_02608

hypothetical protein/hypothetical protein
Segregation and condensation protein B
hypothetical protein/hypothetical protein
Serine/threonine phosphatase stp
UDP-N-acetylmuramoyl-L-alanyl-D-glutamate--L- lysine
ligase

hypothetical protein/N-acetylmuramoyl-L-alanine amidase
sle1
Ribosomal RNA small subunit methyltransferase A
PTS system trehalose-specific EIIBC component/tRNA-Ser
Glutamate synthase [NADPH] large chain
hypothetical protein

hypothetical protein/Nickel-binding periplasmic protein
2-dehydropantoate 2-reductase

hypothetical protein/hypothetical protein

New Junction Evidence
No unassigned new junction evidence found for this population.
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G

F-182 Evolved Population 1 - Predicted Mutations

Position

Mutation

Freq.

Annotation

Gene

Product

10,718

T→A

5.9%

D893E (GAT→GAA)

KNNFDEDG_00013 →

hypothetical protein

10,721

T→A

5.5%

H894Q (CAT→CAA)

KNNFDEDG_00013 →

hypothetical protein

221,357

Δ9 bp

7.0%

coding (810-818/855)

atl_1 →

Bifunctional autolysin

321,615

Δ1 bp

80.4%

coding (118/1122)

citZ →

1,105,996

T→C

5.3%

intergenic (−48/−181)

appA ← /
→ KNNFDEDG_01041

1,198,194

A→G

5.9%

S55S (TCT→TCC)

ywqG ←

1,358,378

G→T

16.9%

E184* (GAA→TAA)

KNNFDEDG_01286 →

1,511,943

C→G

5.6%

intergenic (−5/+170)

rsmC ← / ← rplL

1,841,744

Δ23 bp

100%

coding (409-431/477)

KNNFDEDG_01743 →

hypothetical protein

1,987,003

Δ96,368 –
97,214 bp

100%

n/a

[KNNFDEDG_01864] –
[KNNFDEDG_01952]

89 genes

2,091,225

Δ313 bp

100%

coding (362-674/789)

yycI ←

Citrate synthase 2
Oligopeptide-binding protein AppA/
IS30 family transposase ISSau1
putative protein YwqG
hypothetical protein
Ribosomal RNA small subunit methyltransferase C/
50S ribosomal protein L7/L12

Two-component system WalR/
WalK regulatory protein YycI

New Junction Evidence
Position

Reads (cov)

Score

Freq.

18 (0.100)

14/250

12.3%

23,916 =
= 2,873,603
188,694 =

Gene

Product

coding (186/201)

hlb_1

Phospholipase C

coding (16/825)

hlb_2

Phospholipase C

intergenic (−37/−55)
8 (0.040)

5/272

5.8%

= 202,035

intergenic (+220/−415)

= 1,227,802

intergenic (−530/−310)
17 (0.100)

11/248

11.0%

1,243,428 =
= 1,987,002
255 (1.290)

61/276

2,536,239 =
221 (1.110)

58/278

= 2,536,241
61/278

coding (1478/1755)

KNNFDEDG_01864

hypothetical protein

intergenic (+36/−55)

KNNFDEDG_01951/
KNNFDEDG_01952

hypothetical protein/
IS6 family transposase IS431mec

coding (243/1260)

lyrA

Lysostaphin resistance protein A

intergenic (+194/−60)

rplQ/KNNFDEDG_02464

coding (241/1260)

lyrA

intergenic (+59/−343)

KNNFDEDG_02465/ecfA1

92.1%

= 2,634,949
= 2,694,568

intergenic (+36/−11)
20 (0.140)

7/206

hypothetical protein/
hypothetical protein
IS30 family transposase ISSau5/
hypothetical protein
hypothetical protein/
Enterotoxin type A
Tyrosine recombinase XerC/
SsrA-binding protein

xerC_8/smpB

92.9%

2,633,290 =

186 (0.940)

KNNFDEDG_00216/
KNNFDEDG_00217
KNNFDEDG_00231/
KNNFDEDG_00232
KNNFDEDG_01162/
entA_4

intergenic (+128/+435)

100%

2,083,537 =

2,813,006 =

Annotation

11.2%
intergenic (+293/−70)
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KNNFDEDG_02518/
KNNFDEDG_02519
KNNFDEDG_02631/
KNNFDEDG_02632

50S ribosomal protein L17/
IS3 family transposase ISSau2
Lysostaphin resistance protein A
IS3 family transposase ISSau2/
Energy-coupling factor transporter
ATP-binding protein EcfA1
5S ribosomal RNA (partial)/
tRNA-Asn
5S ribosomal RNA (partial)/
hypothetical protein

H

F-182 Evolved Population 3 - Predicted Mutations

Position

Mutation

Freq.

Annotation

Gene

Product

10,718

T→A

6.4%

D893E (GAT→GAA)

KNNFDEDG_00013 →

hypothetical protein

10,721

T→A

6.0%

H894Q (CAT→CAA)

KNNFDEDG_00013 →

hypothetical protein

58,246

T→G

11.3%

D461E (GAT→GAG)

pncB2 →

119,410

T→A

6.3%

intergenic (+45/−2)

KNNFDEDG_00114 →/
→ KNNFDEDG_00115

220,578

G→T

93.9%

G11* (GGA→TGA)

atl_1 →

860,029

G→C

100%

Q133E (CAA→GAA)

stp ←

Serine/threonine phosphatase stp

1,740,786

A→T

6.1%

M124K (ATG→AAG)

hldE ←

Bifunctional protein HldE

1,979,010

Δ104,360 –
105,207 bp

100%

n/a

[KNNFDEDG_01857] –
[KNNFDEDG_01952]

2,106,920

C→A

14.0%

C323F (TGT→TTT)

serS ←

Serine--tRNA ligase

2,116,111

A→T

6.4%

N216K (AAT→AAA)

recF ←

DNA replication and repair protein RecF

2,456,691

T→A

7.6%

H167Q (CAT→CAA)

bdbD →

Disulfide bond formation protein D

2,697,439

Δ12 bp

16.8%

coding (308-319/933)

cdaR →

CdaA regulatory protein CdaR

2,881,241

C→A

9.7%

A431E (GCA→GAA)

KNNFDEDG_02710 →

hypothetical protein

2,884,494

G→C

6.1%

A159P (GCA→CCA)

KNNFDEDG_02714 →

hypothetical protein

19,681

A→T

11.2%

I463F (ATT→TTT)

topB_2 →

DNA topoisomerase 3

Nicotinate phosphoribosyltransferase pncB2
5S ribosomal RNA (partial)/tRNA-Val
Bifunctional autolysin

96 genes

New Junction Evidence
Position

Reads (cov)

Score

Freq.

11 (0.050)

9/250

6.8%

23,916 =
= 2,873,603
188,694 =

Gene

Product

coding (186/201)

hlb_1

Phospholipase C

coding (16/825)

hlb_2

Phospholipase C

intergenic (−37/−55)
8 (0.040)

5/272

5.8%

= 202,035

intergenic (+220/−415)

= 1,227,802

intergenic (−530/−310)
27 (0.120)

17/248

13.7%

1,243,428 =
= 1,979,009
315 (1.240)

74/278

2,536,240 =
20 (0.080)

12/278

= 2,694,568

coding (66/627)

KNNFDEDG_01857

hypothetical protein

intergenic (−202/−56)

KNNFDEDG_01945/
KNNFDEDG_01946

hypothetical protein/
IS6 family transposase IS431mec

coding (242/1260)

lyrA

Lysostaphin resistance protein A

intergenic (+194/−60)

rplQ/KNNFDEDG_02464

intergenic (+36/−11)
5/206

hypothetical protein/
hypothetical protein
IS30 family transposase ISSau5/
hypothetical protein
hypothetical protein/
Enterotoxin type A
Tyrosine recombinase XerC/
SsrA-binding protein

xerC_8/smpB

6.7%

2,633,290 =

21 (0.110)

KNNFDEDG_00216/
KNNFDEDG_00217
KNNFDEDG_00231/
KNNFDEDG_00232
KNNFDEDG_01162/
entA_4

intergenic (+128/+435)

100%

2,078,190 =

2,813,006 =

Annotation

9.7%
intergenic (+293/−70)
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KNNFDEDG_02518/
KNNFDEDG_02519
KNNFDEDG_02631/
KNNFDEDG_02632

50S ribosomal protein L17/
IS3 family transposase ISSau2
5S ribosomal RNA (partial)/
tRNA-Asn
5S ribosomal RNA (partial)/
hypothetical protein

I

Mu3 Evolved Population 1 - Predicted Mutations

Position

Mutation

Freq.

Annotation

Gene

Product

525,737

T→A

6.7%

N183K (AAT→AAA)

aroC →

Chorismate synthase

595,913

T→A

7.1%

intergenic (−323/−128)

CHIMOCOP_00562 ← /
→ CHIMOCOP_00563

667,649

C→A

10.8%

A232S (GCA→TCA)

mprF ←

Phosphatidylglycerol lysyltransferase

1,038,029

C→A

6.1%

G479C (GGC→TGC)

murE ←

UDP-N-acetylmuramoyl-L-alanyl-D-glutamate-L-lysine ligase

1,053,247

G→C

21.9%

A175G (GCG→GGG)

yjbM ←

GTP pyrophosphokinase YjbM

1,053,291

Δ11 bp

25.6%

coding (470-480/636)

yjbM ←

GTP pyrophosphokinase YjbM

1,063,395

C→G

100%

G302A (GGT→GCT)

gsiC ←

Glutathione transport system permease protein GsiC

1,190,788

G→C

5.4%

intergenic (+58/+10)

xerC_4 → /
← CHIMOCOP_01148

Tyrosine recombinase XerC/
hypothetical protein

1,190,789

G→T

5.4%

intergenic (+59/+9)

xerC_4 → /
← CHIMOCOP_01148

Tyrosine recombinase XerC/
hypothetical protein

1,471,363

T→A

14.2%

D177V (GAT→GTT)

pbuG ←

1,997,417

Δ34 bp

26.6%

coding (692-725/1335)

CHIMOCOP_01914 →

hypothetical protein

1,997,508:1

+A

24.4%

coding (783/1335)

CHIMOCOP_01914 →

hypothetical protein

1,998,102

Δ21 bp

55.7%

coding (42-62/789)

yycI →

2,638,830

T→A

7.7%

intergenic (+130/−47)

CHIMOCOP_02486 → /
→ CHIMOCOP_02487

2,817,652

A→T

9.9%

D177V (GAT→GTT)

trxB →

Thioredoxin reductase

2,817,655

A→T

7.1%

E178V (GAG→GTG)

trxB →

Thioredoxin reductase

2,817,692

C→A

7.0%

F190L (TTC→TTA)

trxB →

Thioredoxin reductase

1

Δ25,109 bp

100%

n/a

[CHIMOCOP_02739]–
CHIMOCOP_02765

hypothetical protein/hypothetical protein

Guanine/hypoxanthine permease PbuG

Two-component system WalR/
WalK regulatory protein YycI
Phosphomevalonate kinase/hypothetical protein

27 genes

New Junction Evidence
Position

Reads (cov)

Score

Freq.

= 2,003,414
140 (0.600)
2,056,342 =

49/272

Annotation

Gene

coding (464/480)

rlmH

intergenic (+30/−557)

CHIMOCOP_01969/
CHIMOCOP_01970

51.8%

- 51 -

Product
Ribosomal RNA large subunit
methyltransferase H
hypothetical protein/hypothetical protein

J

Mu3 Evolved Population 2 - Predicted Mutations

Position

Mutation

Freq.

Annotation

Gene

Product

667,645

A→T

8.5%

I233K (ATA→AAA)

mprF ←

Phosphatidylglycerol lysyltransferase

667,719

T→A

27.1%

L208F (TTA→TTT)

mprF ←

Phosphatidylglycerol lysyltransferase

1,004,168

C→A

6.7%

A768D (GCT→GAT)

atl_2 →

Bifunctional autolysin

1,247,036

T→A

8.7%

intergenic (−136/−46)

CHIMOCOP_01215 ← /
→ agrB

1,388,986

Δ103 bp

100%

coding (75-177/933)

cdaR ←

1,529,949

T→A

8.7%

N232I (AAT→ATT)

CHIMOCOP_01495 ←

hypothetical protein

1,624,629

T→A

11.6%

S108S (TCA→TCT)

CHIMOCOP_01584 ←

hypothetical protein

1,813,207

T→A

7.2%

I69N (ATC→AAC)

CHIMOCOP_01751 →

hypothetical protein

1,830,991

T→G

5.6%

intergenic (+65/+33)

cocE → /
← CHIMOCOP_01774

Cocaine esterase/hypothetical protein

1,998,222

Δ1 bp

100%

coding (162/789)

yycI →

2,015,936

Δ16 bp

11.1%

coding (306-321/2007)

mecA_2 ←

2,063,528

G→T

5.7%

W114L (TGG→TTG)

CHIMOCOP_01975 →

2,181,789

C→G

6.5%

K88N (AAG→AAC)

yecD ←

2,498,614

C→A

5.1%

Q335K (CAA→AAA)

ruvB_2 →

2,792,704

G→T

5.6%

T70N (ACT→AAT)

CHIMOCOP_02635 ←

2,817,652

A→T

6.7%

D177V (GAT→GTT)

trxB →

Thioredoxin reductase

2,817,655

A→T

6.9%

E178V (GAG→GTG)

trxB →

Thioredoxin reductase

2,817,692

C→A

10.3%

F190L (TTC→TTA)

trxB →

Thioredoxin reductase

1

Δ25,109 bp

100%

n/a

[CHIMOCOP_02739]–
CHIMOCOP_02765

hypothetical protein/Accessory gene regulator protein B
CdaA regulatory protein CdaR

Two-component system WalR/
WalK regulatory protein YycI
PBP2a family beta-lactam-resistant peptidoglycan
transpeptidase MecA
hypothetical protein
Isochorismatase family protein YecD
Holliday junction ATP-dependent DNA helicase RuvB
hypothetical protein

27 genes

New Junction Evidence
Position

Reads (cov)

Score

Freq.

= 2,011,770
13 (0.030)

9/276

= 2,011,770
2,021,721

31/276

Gene

intergenic (−56/−202)

CHIMOCOP_01927/
CHIMOCOP_01928

coding (1081/1110)

nagC

intergenic (−56/−202)

CHIMOCOP_01927/
CHIMOCOP_01928

IS6 family transposase IS431mec/
hypothetical protein

coding (926/1065)

glpE_2

Thiosulfate sulfurtransferase GlpE

5.6%

2,020,072 =

68 (0.180)

Annotation

14.9%
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Product
IS6 family transposase IS431mec/
hypothetical protein
N-acetylglucosamine repressor

K

Mu3 Evolved Population 3 - Predicted Mutations

Position

Mutation

Freq.

Annotation

Gene

Product

1,219,755

C→A

13.5%

A441S (GCT→TCT)

CHIMOCOP_01183 ←

hypothetical protein

1,624,647

G→T

5.9%

S102R (AGC→AGA)

CHIMOCOP_01584 ←

hypothetical protein

1,703,572

A→T

5.1%

S135T (TCT→ACT)

CHIMOCOP_01655 ←

hypothetical protein

1,755,635

G→T

7.0%

intergenic (−36/−190)

mhqR ← / → yjdJ

1,996,837

Δ1 bp

8.8%

coding (112/1335)

CHIMOCOP_01914 →

hypothetical protein

1,998,047

Δ5 bp

8.4%

coding
(1322-1326/1335)

CHIMOCOP_01914 →

hypothetical protein

1,998,252

Δ1 bp

100%

coding (192/789)

yycI →

Two-component system WalR/
WalK regulatory protein YycI

2,181,767

C→A

6.5%

D96Y (GAC→TAC)

yecD ←

Isochorismatase family protein YecD

2,600,343

C→A

8.6%

Q60K (CAA→AAA)

sdrC →

Serine-aspartate repeat-containing protein C

2,817,652

A→T

8.0%

D177V (GAT→GTT)

trxB →

Thioredoxin reductase

2,871,009

C→A

12.6%

Q418K (CAA→AAA)

CHIMOCOP_02720 →

hypothetical protein

1

Δ25,109 bp

100%

n/a

[CHIMOCOP_02739]–
CHIMOCOP_02765

27 genes

HTH-type transcriptional regulator MhqR/
putative protein YjdJ

New Junction Evidence
Position

Reads (cov)

Score

Freq.

= 2,003,414
276 (0.890)
2,056,342

74/272

Annotation

Gene

coding (464/480)

rlmH

intergenic (+30/−557)

CHIMOCOP_01969/
CHIMOCOP_01970

82.3%
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Product
Ribosomal RNA large subunit
methyltransferase H
hypothetical protein/hypothetical protein

Table 5: Predicted genetic mutations of the evolved Staphylococcus aureus strains. Mutations
potentially conferring alcohol tolerance predicted using programs breseq and Integrative
Genomics Viewer (IGV). Wood 46 evolved populations 1 (Table 4A), 2 (Table 4B), 3 (Table 4C).
Wichita evolved populations 1 (Table 4D), 2 (Table 4E), 3 (Table 4F). F-182 evolved populations
1 (Table 4G) and 3 (Table 4H). F-182 evolved population 2 was not able to align with reference
genome, thus mutations were unable to be calculated. Mu3 evolved populations 1 (Table 4I),
2 (Table 4J), 3 (Table 4K). Mutations present in the ancestral populations were considered false
mutations and were omitted from the tables. For mutations, “→” indicates a single nucleotide
polymorphism (SNP), “x2” indicates a duplication, “+” indicates an insertion, and “Δ” indicates a
deletion. Green highlights represent mutations fixed in the population with 100% frequency,
purple highlights represent mutations present in plasmids, and orange highlights represent that the
end of a junction aligns to more than one location on the reference genome.
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Wood 46
Wichita
F-182
Mu3

Max Growth Rate

Carrying Capacity

Population Size (CFUs/mL)

Ancestral

0.454

1.048

1.41 × 109

Evolved 1

0.862

1.209

1.81 × 109

Evolved 2

0.325

1.140

2.23 × 109

Evolved 3

0.522

1.215

2.74 × 109

Ancestral

1.438

1.017

1.25 × 109

Evolved 1

0.944

1.123

9.63 × 108

Evolved 2

1.217

1.224

1.85 × 109

Evolved 3

1.270

1.133

1.79 × 109

Ancestral

0.511

1.035

1.58 × 108

Evolved 1

1.489

1.144

1.23 × 109

Evolved 2

1.277

1.267

1.35 × 109

Evolved 3

1.426

1.239

2.01 × 109

Ancestral

1.323

1.228

3.82 × 109

Evolved 1

1.352

1.299

2.02 × 109

Evolved 2

1.243

1.307

1.52 × 109

Evolved 3

1.273

1.304

1.94 × 109

Table 6: Evolved Staphylococcus aureus population growth curve metrics. Means values of max
growth rate and carrying capacity taken from the microplate spectrophotometer measurements
(n = 6). Analysis using GrowthCurver package in R. Ancestral strains highlighted in blue.
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Appendix 1: Staphylococcus aureus Strain Details
Staphylococcus aureus subsp. aureus Rosenbach – ATCC 10832
Strain Designation: Wood 46
Product Type: Preceptrol culture
BSL: 2
Isolation Source: Natural isolate
Susceptibility: Methicillin sensitive
Genotype: pvl negative
SCCmec: n/a
spa type Ridom: n/a
spa type Kreiswith: n/a
Genome Length: 2,834,988 nt
Number of Contigs: 1
GC Content: 32.84%

- 61 -

Staphylococcus aureus subsp. aureus Rosenbach – ATCC 29213
Strain Designation: Wichita
Product Type: Preceptrol culture
BSL: 2
Isolation Source: Wound
Susceptibility: Methicillin sensitive
Genotype: pvl negative
SCCmec: n/a
spa type Ridom: t002
spa type Kreiswith: TJMBMDMGMK
Genome Length: 2,809,261 nt
Number of Contigs: 2
GC Content: 32.85%

- 62 -

Staphylococcus aureus subsp. aureus Rosenbach – ATCC 43300
Strain Designation: F-182
Product Type: Preceptrol culture, drug-resistant bacterium
BSL: 2
Isolation Source: Clinical isolate
Susceptibility: Methicillin resistant, Oxacillin resistant
Genotype: pvl negative
SCCmec: type II
spa type Ridom: t007
spa type Kreiswith: WGKKKKAOM
Genome Length: 2,946,738 nt
Number of Contigs: 2
GC Content: 32.73%

- 63 -

Staphylococcus aureus subsp. aureus Rosenbach – ATCC 700698
Strain Designation: Mu3 [NRS2]
Product Type: Drug-resistant bacterium
BSL: 2
Isolation Source: Sputum from lung cancer patient with MRSA pneumonia
Susceptibility: Methicillin resistant, heterogeneous susceptibility to vancomycin
Genotype: pvl negative
SCCmec: type II
spa type Ridom: t002
spa type Kreiswith: TJMBMDMGMK
Genome Length: 2,904,682 nt
Number of Contigs: 2
GC Content: 32.85%
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Appendix 2: QIAGEN DNeasy® Blood & Tissue Kit Protocol
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Appendix 3: Equations
Dilution Plate Count
𝐶=

𝑛
𝐷𝑣

𝐶 = Bacterial stock (CFUs/mL)
𝑛 = Number of colonies
𝐷 = Dilution factor
𝑣 = Volume plated (mL)
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Bacterial Survival
𝑅 = −log!"

𝐶#
𝐶$

𝑅 = Log10 reduction
𝐶# = Initial bacteria concentration (CFUs/mL)
𝐶$ = Final bacteria concentration (CFUs/mL)
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Growth Curve Best Fit Line
𝑁% =

𝐾
𝐾−𝑁
1 + 0 𝑁 " 1 𝑒 &'%
"

𝑁% = Population size at time t
𝐾 = Carrying capacity
𝑁" = Initial population size
𝑟 = Intrinsic growth rate of the population
𝑡 = Time in hours
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